Do endometrial cancer patients benefit from metformin intake?

Ginekologia Polska

Volumn 86, Issue 6, 2015, Pages 419-423

  Lemańska, Agnieszka ^a   Zaborowski, Mikołaj ^a   Spaczyński, Marek ^a   Nowak Markwitz, Ewa ^a  

^a Klinika Onkologii Ginekologicznej Ginekologiczno Potozniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznaniu   (Poland)

Author keywords

Diabetes; Endometrial cancer; Metabolic disorders; Metformin; Survival

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; METFORMIN;

ADULT; AGED; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84939476914     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/2397     Document Type: Article

References (29)

1. Kacalska-Janssen O, Rajtar-Ciosek A, Zmaczyński A, [et al.]. Markers of insulin resistance in perimenopausal women with endometrial pathology. Ginekol Pol. 2013, 84 (11), 922-929.
2. Wang Y, Zhu Y, Zhang L, [et al.]. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 2012, 322 (2), 223-231.
3. Berstein LM, Kvatchevskaya JO, Poroshina TE, [et al.]. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004, 130 (11), 687-693.
4. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012, 7 (3): e33411.
5. Zhang P, Li H, Tan X, [et al.]. Association of metformin use with cancer incidence and mortality:a meta-analysis. Cancer Epidemiol. 2013, 37 (3), 207-218.
6. Zhang Z-J, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes:a systematic review and meta-analysis. Diabetes Obes Metab. 2014, 16 (8), 707-710.
7. Currie CJ, Poole CD, Jenkins-Jones S, [et al.]. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012, 35 (2), 299-304.
8. Zhang Q, Celestino J, Schmandt R, [et al.]. Chemopreventive effects of metformin on obesityassociated endometrial proliferation. Am J Obstet Gynecol. 2013, 209 (1), 24.e1-24.e12.
9. Cantrell LA, Zhou C, Mendivil A, [et al.]. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2010, 116 (1), 92-98.
10. Tan BK, Adya R, Chen J, [et al.]. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2011, 96 (3), 808-816.
11. Dong L, Zhou Q, Zhang Z, [et al.]. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res. 2012, 38 (8), 1077-1085.
12. Hanna RK, Zhou C, Malloy KM, [et al.]. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012, 125 (2), 458-469.
13. Zhang Z, Dong L, Sui L, [et al.]. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer. 2011, 21 (2), 213-221.
14. Xie Y, Wang Y-L, Yu L, [et al.]. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 2011, 126 (3-5), 113-120.
15. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988, 67 (3), 460-464.
16. Zhou G, Myers R, Li Y, [et al.]. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001, 108 (8), 1167-1174.
17. An H-J, Lee Y-H, Cho N-H, [et al.]. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology. 2002, 41 (5), 437-445.
18. Grosman-Dziewiszek P, Dziegiel P, Zabel M. Disturbance of gene expression in endometrial cancer as therapy aim. Ginekol Pol. 2011, 82 (4), 276-280.
19. Ben Sahra I, Laurent K, Loubat A, [et al.]. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008, 27 (25), 3576-3586.
20. Mu N, Wang Y, Xue F. Metformin: a potential novel endometrial cancer therapy. Int J Gynecol Cancer. 2012, 22 (2), 181.
21. Lin C-C, Yeh H-H, Huang W-L, [et al.]. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol. 2013, 49 (2), 241-250.
22. Ko J-C, Huang Y-C, Chen H-J, [et al.]. Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells. Basic Clin Pharmacol Toxicol. 2013, 113 (1), 56-65.
23. Gotlieb WH, Saumet J, Beauchamp M-C, [et al.]. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008, 110 (2), 246-250.
24. Session DR, Kalli KR, Tummon IS, [et al.]. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol. 2003, 17 (5), 405-407.
25. Stanosz S. An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol. 2009, 30 (4), 365-369.
26. Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: a casecontrol analysis. Gynecol Oncol. 2013, 129 (3), 565-569.
27. Ko EM, Walter P, Jackson A, [et al.]. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014, 132 (2), 438-442.
28. Nevadunsky NS, Van Arsdale A, Strickler HD, [et al.]. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014, 132 (1), 236-240.
29. www.clinicaltrials.gov [Internet]. [cited 2014 May 26]. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01205672?term=metformin+endometrial+cancer&rank=2